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Abstract 
 
Objective To investigate whether enlarged perivascular spaces within the basal ganglia or 
deep cerebral white matter are risk factors for intracranial hemorrhage in patients taking oral 
anticoagulants (OAC), independent of established clinical and radiological risk factors, we 
conducted a post hoc analysis of CROMIS-2 (AF), a prospective inception cohort study. 
 
Methods Patients with atrial fibrillation and recent TIA or ischaemic stroke underwent 
standardised MR imaging prior to starting OAC. We rated basal ganglia (BGPVS) and 
centrum semiovale (CSOPVS) perivascular spaces, cerebral microbleeds (CMBs), white 
matter hyperintensities and lacunes. We dichotomized the PVS rating using a threshold of 
>10 PVS in the relevant region of either cerebral hemisphere. The primary outcome was 
symptomatic intracranial hemorrhage (sICH). We identified risk factors for sICH using Cox 
regression. 
 
Results 1386 participants with available clinical and imaging variables were followed up for 
a mean of 2.34 years. 14 sICH occurred (11 intracerebral). In univariable analysis, diabetes, 
CMB presence, lacune presence and >10 BGPVS, but not CSOPVS, were associated with 
sICH. In a multivariable model incorporating all variables with significant associations in 
univariable analysis, >10 BGPVS (HR 8.96, 95% CI 2.41 – 33.4, p = 0.001) and diabetes 
(HR 3.91, 95% CI 1.34 – 11.4) remained significant risk factors for sICH.  
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Conclusion Enlarged BGPVS might be a novel risk factor for OAC-related ICH. The 
strength of this association and potential use in predicting ICH in clinical practice should be 
investigated in larger cohorts. 
Introduction 
 
Within the brain, the perivascular space is the compartment bounded by the wall of 
penetrating cerebral blood vessels and the glia limitans, which might facilitate fluid 
circulation and clearance of soluble waste, including amyloid-beta, from brain parenchyma 1-
3. In age and disease, perivascular spaces may enlarge and become MRI-visible, as fluid-
filled structures most easily assessed within the basal ganglia and the centrum semiovale 
white matter. Cross-sectional studies of intracerebral haemorrhage (ICH) survivors have 
associated enlarged basal ganglia perivascular spaces (BGPVS) with deep ICH, increased 
white matter hyperintensity volume, and deep cerebral microhemorhages (CMBs), and 
enlarged centrum semiovale perivascular spaces (CSOPVS) with lobar ICH and cerebral 
amyloid angiopathy (CAA) 4-6. In cognitively-impaired patients, BGPVS are associated with 
hypertension, deep CMBs and lacunes, and CSOPVS with lobar CMBS, cortical superficial 
siderosis and Alzheimer’s disease 7-9.  
Together, these data suggest that BGPVS might be markers of deep perforator arteriopathy, 
and CSOPVS of amyloid-beta pathology, including CAA. PVS might therefore also indicate 
increased ICH risk. A prospective study of patients with TIA or ischaemic stroke found an 
association between >20 BGPVS in either hemisphere and incident ICH, though this was not 
statistically significant when adjusted for vascular risk factors 10. We wished to investigate 
this question in patients with atrial fibrillation taking oral anticoagulants (OAC) after 
ischaemic stroke or TIA. We hypothesized that BGPVS and CSOPVS would be associated 
with anticoagulant-related intracranial hemorrhage (OAC-ICH), independent of other 
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markers of cerebral small vessel disease linked to OAC-ICH, notably CMBs and white matter 
hyperintensities 11,12. 
 
Methods 
 
Study design 
We conducted a post hoc analysis of the CROMIS-2 (AF) study, a multicenter prospective 
inception cohort study of the relationship between cerebral microbleeds and anticoagulant-
related symptomatic intracranial hemorrhage. The design, full description of the cohort, and 
primary results of this study have been published elsewhere11. Briefly, we recruited adult 
patients with atrial fibrillation initiating oral anticoagulation after recent ischaemic stroke or 
TIA from 79 hospitals in the United Kingdom and one in the Netherlands, between August 
2011 and July 2015. MR imaging was performed at baseline according to a standardised 
protocol, including axial T1- and T2 –weighted, coronal fluid-attenuated inversion recovery 
(FLAIR), diffusion-weighted, and T2*-weighted GRE sequences. To reduce selection bias, 
imaging was performed after study enrolment, and we only enrolled participants whose 
responsible clinician had already decided to treat with an anticoagulant. We followed up 
participants for 24 months using multiple overlapping methods, including postal 
questionnaires, telephone interviews, and hospital episode statistics. The primary outcome 
was symptomatic intracranial hemorrhage (sICH), defined as brain-imaging evidence of non-
traumatic spontaneous intracranial hemorrhage with appropriate clinical symptoms.  
 
Neuroimaging analysis 
We analyzed participants’ MR imaging for markers of cerebral small vessel disease 
according to STRIVE definitions 13. Trained research fellows (JGB, DW, GB, HD) 
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performed ratings blinded to the occurrence of sICH during follow-up, using validated rating 
scales where available. One of two raters (GB, HD) rated PVS at the level of the basal 
ganglia and centrum semiovale separately, using a five-level scale which assigns a score of 0 
to no visible perivascular spaces, 1 to 1 – 10, 2 to 11 – 20, 3 to >21 – 40, and 4 to >40 
perivascular spaces 14.   We rated each hemisphere, unless prevented by the presence of a 
focal lesion, and used the higher of the two values. We rated cerebral microbleeds (CMBs) 
using the Microbleed Anatomical Rating Scale 15, and white matter hyperintensities using the 
Age-Related White Matter Changes (ARWMC) scale (DW) 16. We identified and counted 
lacunes (GB, HD). 
Given the possibility that enlarged perivascular spaces might predominantly reflect cerebral 
atrophy, one of two raters (GB, JGB) rated each participant’s imaging using the simplified 
Pasquier Scale 17, which quantifies the global severity of cortical atrophy (GCA) on a four-
level scale (0: no atrophy, 1: sulcal widening, 2: gyral volume loss, 3: ‘knife-blade’ atrophy).  
We used axial T1 or FLAIR images for rating if available, and inverted axial T2 images if 
not. When a significant focal lesion was present, we rated the non-lesioned hemisphere. 
When more than one rater rated a marker, we assessed inter-rater agreement on a random 
sample using Cohen’s Kappa, weighted for ordinal variables. 
 
Statistical analysis 
We investigated the association between enlarged perivascular spaces and the hazard of 
symptomatic intracranial hemorrhage using Cox regression. As well as BGPVS and 
CSOPVS, we prespecified age, sex, clinical history of diabetes mellitus and clinical history of 
hypertension as clinical independent variables and ARWMC score, cerebral microbleeds, 
lacunes and GCA as additional imaging independent variables. We chose not to include 
cortical superficial siderosis (cSS) due to its very low prevalence in our study population. 
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Using a predetermined threshold previously associated with the presence of other small 
vessel disease markers 14 and incorporated into a validated composite small vessel disease 
score as representing moderate to severe PVS18, we dichotomised perivascular space counts 
in our analysis as 0 – 10 or >10, equivalent to a PVS score of 0 – 1 and 2 – 4 respectively. 
We dichotomised cerebral microbleeds and lacunes as present or absent. We included the 
ARWMC score as a continuous variable. As very few participants received a GCA rating of 
three, we combined categories 2 and 3 to give a three-level ordinal variable comprising no 
atrophy (0), minor atrophy (1), and moderate-severe atrophy (2-3). To reduce the risk of 
overfitting, we initially performed univariable analysis for each variable, and included only 
variables with an association at the 20% level in our final multivariable analysis. We checked 
the proportional hazards assumption using visual inspection of log-log plots of the log 
cumulative hazard against log time and through post-estimation tests based on Schoenfeld 
residuals. We summarized our results graphically using plots of the Kaplan-Meier failure (1 – 
survival) function. Statistical analysis was performed using Stata version 15.0. 
 
Standard Protocol Approvals, Registrations, and Patient Consents 
The UK National Health Service Research Ethics Committee approved the CROMIS-2 study. 
Patients with capacity provided written informed consent. We obtained proxy written 
informed consent if patients lacked capacity to consent, following relevant local legislation. 
 
Data Availability 
We will share anonymized data on reasonable request, following consideration by the 
CROMIS-2 steering committee and execution of a data sharing agreement. Requests should 
be submitted to d.werring@ucl.ac.uk. 
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Results 
 
The primary analysis of the CROMIS-2(AF) study included 1447 participants who met the 
main study inclusion criteria and had follow-up data available. Of these, 1386 participants 
(95.8%) had all additional variables of interest needed for this secondary analysis (Figure 1). 
Participants excluded from our secondary analysis due to missing variables were more likely 
to be female and have hypertension.  As other variables were comparable (Table 1) and the 
overall proportion of missing data was very low, we performed a complete case analysis.  
During 3251 participant-years of follow-up, 14 sICH occurred (11 intracerebral, two 
subdural, 1 subarachnoid). The median time from anticoagulation initiation to sICH was 272 
days (IQR 211 – 657). Of the ten intracerebral haemorrhages for which data on location was 
available, two were deep, four were infratentorial, and four were lobar. Table 2 summarizes 
the clinical and radiological characteristics of participants with and without sICH during 
follow-up.  Interrater agreement for dichotomized PVS score was excellent (k = 0.82) within 
the basal ganglia and substantial (k = 0.80) within the centrum semiovale (n = 50). 
Agreement for GCA rating was moderate (k = 0.53; n = 100), comparable to that in other 
existing literature 19.  We observed a weak correlation between GCA and BGPVS grade 
(Spearman’s rho 0.17, 95% CI 0.12 – 0.22), but not CSOPVS grade (r = 0.04, 95% CI -0.01 – 
0.01). 
Univariable Cox regression showed associations between BGPVS, diabetes, lacune presence, 
and cerebral microbleed presence and sICH (Table 3). We found no evidence of an 
association between CSOPVS and sICH. In a multivariable model incorporating diabetes, 
BGPVS, cerebral microbleed presence and lacune presence, we found strong evidence of an 
association with sICH for enlarged BGPVS and diabetes, and weak evidence of an 
association for cerebral microbleed presence. No evidence of an association was found for 
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lacune presence. Figure 2 shows the cumulative incidence of sICH during study follow-up 
for participants with 0 – 10 and >10 BGPVS. The absolute rate of sICH in participants with 
>10 BGPVS was 1.38/100 participant-years (95% CI 0.69 – 2.47), compared to 0.12/100 
participant-years (95% CI 0.025 – 0.36) in participants with 0 – 10 BGPVS. 
 Given the number of variables included in our multivariable model relative to the number of 
outcome events, we performed additional sensitivity analyses, testing each combination of 
BGPVS presence and diabetes, cerebral microbleed presence or lacune presence individually 
(Table 4). The result of each analysis was similar to that of the main multivariable model. We 
also undertook a sensitivity analysis to investigate the effect of dichotomising PVS as 0 – 20 
or >20, rather than 0 – 10 or >10. Using this threshold, we did not find an association 
between higher BGPVS or CSOPVS counts and sICH (BGPVS: HR 1.0, 95% CI 0.13 – 7.5; 
CSOPVS: HR 1.3, 95% CI 0.36 – 4.6);  however, few participants in our study had counts 
>20 in either location (Table 2), and confidence intervals for both estimates were wide. 
For each model, visual inspection of log-log plots suggested no violation of the proportional 
hazards assumption. Although post-estimation tests provided some evidence that the 
assumption was violated for hypertension (p = 0.037), the estimate of the hazard ratio for 
sICH for hypertension provided no evidence for an association, and hypertension was not 
included in our multivariable model. 
 
Discussion 
 
Our main finding is an association between enlarged PVS within the basal ganglia, but not 
centrum semiovale, and OAC-ICH, independent of major vascular risk factors and other 
markers of cerebral small vessel disease. The estimate and 95% confidence interval of the 
hazard ratio was consistent with a clinically meaningful association, and was highly 
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statistically significant, though lacked precision. Although preliminary, our finding raises the 
possibility that enlarged BGPVS might be a clinically-relevant marker of OAC-ICH risk. 
Other studies have provided supportive observational evidence that incorporating small 
vessel disease markers, specifically CMB presence and WMH severity, can improve the 
performance of clinical risk scores for ICH 11,12, and the current analysis  suggests that 
incorporating BGPVS status into these scores might usefully be investigated.  An advantage 
of BGPVS status as a marker might be that it can be quantified on axial T2 imaging, a routine 
component of nearly all clinical MRI brain imaging. 
Our findings add to the evidence linking enlarged PVS to cerebrovascular disease, but why 
PVS enlargement might occur in the setting of hemorrhage-prone cerebral small vessel 
disease remains unclear. PVS enlargement might reflect extravasation of fluid across 
damaged small vessel walls, possibly compounded by recruitment of inflammatory cells to 
the perivascular space, where they might promote further loss of blood-brain barrier integrity 
and impair perivascular fluid transport 20. In cerebral amyloid angiopathy, perivascular 
aggregation of amyloid-beta may also impair drainage 21, but this is less likely to mediate the 
association between BGPVS and ICH we observed. It is possible that more advanced cerebral 
small vessel disease might lead directly to PVS enlargement through ischemic brain atrophy. 
We consider this less likely, as we corrected for a measure of overall cerebral atrophy, and 
observed an association which was independent of other cerebral small vessel disease 
markers, more consistent with BGPVS enlargement being a sensitive marker or early feature 
of cerebral small vessel disease. Finally, the association between BGPVS and ICH might be 
mediated by a shared underlying mechanism. For example, arterial stiffening has recently 
been associated with BGPVS 22, adjusted for major vascular risk factors, and also with deep 
ICH cross-sectionally and new CMB formation prospectively 23,24. By reducing damping of 
the cardiac impulse and increasing transmission of pulsatile force to small cerebral arteries 25, 
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arterial stiffening might increase ICH risk, and promote PVS formation by altering small 
vessel pulsatility, thought to be a key driver of perivascular fluid transport 26,27. 
Unexpectedly, we did not find an association between CSOPVS and sICH, despite evidence 
linking CSOPVS to cerebral amyloid angiopathy. We considered whether CSOPVS might 
simply be more difficult to measure reliably than BGPVS, leading to increased statistical 
noise and difficulty in detected any associations which do exist, but our excellent interrater 
reliability for both BGPVS and CSOPVS argues against this. More likely explanations 
include the low specificity of the association between CSOPVS and CAA, as CSOPVS 
enlargement also occurs in Alzheimer’s disease without clinical CAA, and the low proportion 
of our study population (3%) who met modified Boston criteria for CAA, probably because 
such patients are not generally viewed as eligible for anticoagulation. Lastly, differences in 
regional vascular anatomy might contribute. Whereas the hemispheric white matter is 
supplied by penetrating branches of distal cortical arteries, the basal region of the brain is 
supplied by small perforating arteries which arise directly from large cerebral arteries. These 
vessels are therefore exposed to higher peak blood pressures 28, and so to the effects of 
systemic hypertension and, potentially, arterial stiffening. BGPVS enlargement might 
therefore be a more sensitive marker of these processes than CSOPVS. 
As a secondary analysis of CROMIS-2 (AF), our study has methodological strengths: this 
was a large, multicenter prospective inception cohort study, recruiting a population similar in 
age, prevalence of vascular risk factors, and stroke severity, to the overall case mix of UK 
stroke units29. We obtained a >97% follow-up rate, and sICH events were adjudicated 
centrally without knowledge of CMB or PVS status. The MR imaging protocol was 
standardized between sites, and imaging markers were rated blinded to sICH during follow-
up. We obtained substantial or excellent interrater agreement for key small vessel disease 
markers. 
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Our study has limitations, which we acknowledge. Most importantly, as a post hoc analysis, 
our results should be considered hypothesis-generating. The need for verification of our 
findings in an independent cohort is emphasised by the low number of outcome events 
observed, although we attempted to limit overfitting of our multivariable regression model by 
using a variable-selection procedure, and undertook additional sensitivity analyses. We 
included a clinical history of hypertension as an independent variable in our analysis, but we 
lacked data on BP control prior to or during the study, as well as details of anticoagulation 
control intensity for warfarin-treated patients, and adherence to anticoagulation for all 
participants. As eligibility for anticoagulation was an inclusion criterion for the study, our 
cohort might not be fully representative of the overall population of AF patients in whom 
anticoagulation is considered, and although study-specific imaging was performed after the 
decision to treat with anticoagulation was made, we cannot exclude the possibility that patient 
selection to our study may have been influenced by the results of imaging already performed 
as part of clinical care. The generalizability of our result may be further affected by our 
predominantly (95%) Caucasian study population, and the low proportion of patients taking 
direct oral anticoagulants (37%), which are increasingly preferred to warfarin in clinical 
practice due to their lower risk of ICH. Of the 14 ICH events observed in our study, 12 were 
in warfarin-treated patients.  
As well as validating our findings, further study in a large independent cohort is needed to 
allow precise estimation of the strength of the association between BGPVS and OAC-ICH, 
and investigation of its association with BGPVS count or score, rather than the dichotomized 
rating used in this study. We failed to observe an association between >20 BGPVS and sICH, 
in contrast to a previous study 10, which we attribute to the low prevalence of higher PVS 
counts in our study and the small number of outcome events observed. However, the 
relationship between BGPVS count and sICH might also be non-linear, showing a ‘threshold’ 
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effect, and larger, better-powered studies might clarify this. Such studies might also 
investigate the relationship between PVS and different locations of sICH (for example, lobar 
vs deep/infratentorial intracerebral haemorrhage, or intracerebral vs subdural or subarachnoid 
haemorrhage), which have different biological mechanisms. 
The clinical importance of our finding will depend on whether adding BGPVS status to 
existing ICH risk models can improve their performance, which we chose not to investigate 
in our cohort due to the risk of overfitting, and clarification of whether BGPVS are also 
associated with ischaemic stroke, and the strength of this association, if present, relative to 
that with ICH. This information is needed to establish whether BGPVS status should 
influence the selection of pharmacological and non-pharmacological treatments for stroke 
prevention in patients with AF in clinical practice. Large-scale global collaboration between 
cohort studies of OAC-related ICH, such as the Microbleeds International Collaborative 
Network (MICON) 30, might provide a means by which to investigate these unanswered 
questions. 
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Table 1: characteristics of study population 
Comparison of characteristics of participants included in analysis to those excluded for 
missing at least one variable. Values show prevalence for categorical variables, and mean 
(SD) or median (IQR) for continuous variables.  
 
Characteristic Included (n = 1386) Excluded (n = 61) 
Age 75.8 (10.4) 78.2 (9.2) 
Female sex 575/1386 (41.5%) 36/61 (59.0%) 
Hypertension 876/1386 (63.2%) 30/39 (76.9%) 
Diabetes 229/1386 (16.5%) 13/59 (22.03%) 
>10 BGPVS 363/1386 (26.2%) 14/48 (29.2%) 
>10 CSOPVS 665/1386 (48.0%) 23/48 (47.9%) 
Lacune presence 286/1386 (20.6%) 9/41 (22.0%) 
CMB presence 288/1386 (20.8%) 16/61 (26.2%) 
ARWMC score 1 (0 – 3) 1 (0 – 3) 
cSS presence 5/1386 (0.35%) 0 (0%) 
0 461/1386 (33.3%) 17/59 (28.8%) 
1 613/1386 (44.2%) 29/59 (49.2%) 
GCA score 
2 - 3 312/1386 (22.5%) 13/59 (22.0%) 
sICH during follow-up 14/1386 (1%) 0/61 (0%) 
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Table 2: characteristics of patients with and without sICH 
Comparison of characteristics of participants included in analysis with and without sICH 
during follow-up. Values show prevalence for categorical variables, and mean (SD) or 
median (IQR) for continuous variables.  
Characteristic No sICH (n = 1372) sICH (n = 14) 
Age 75.8 (10.4) 78.6 (10.5) 
Female sex 570/1372 (41.6%) 5/14 (35.7%) 
Hypertension 868/1372 (63.3%) 8/14 (57.1%) 
Diabetes 223/1372 (16.3%) 6/14 (42.9%) 
>10 BGPVS 352/1372 (25.7%) 11/14 (78.6%) 
0 62/1372 (4.5%) 0/14 (0%) 
1 - 10 958/1372 (69.8%) 3/14 (21.4%) 
11 - 20 247/1372 (18.0%) 10/14 (71.4%) 
21 - 40 86/1372 (6.3%) 1/14 (7.1%) 
BGPVS 
count 
>40 19/1372 (1.4%) 0/14 (0%) 
>10 CSOPVS 658/1372 (48.0%) 7/14 (50.0%) 
0 80/1372 (5.8%) 0/14 (0.0%) 
1 - 10 634/1372 (46.2%) 7/14 (50.0%) 
11 - 20 421/1372 (30.7%) 4/14 (28.6%) 
21 - 40 197/1372 (14.4%) 3/14 (21.4%) 
CSOPVS 
count 
>40 40/1372 (2.9%) 0/14 (0.0%) 
Lacune presence 280/1372 (20.4%) 6/14 (42.9%) 
CMB presence 281/1372 (20.5%) 7/14 (50.0%) 
CMB Deep 113/1372 (8.2%) 1/14 (7.1%) 
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Lobar 102/1372 (7.4%) 3/14 (21.4%) distribution 
Mixed 66/1372 (4.8%) 3/14 (21.4%) 
ARWMC score 1 (0 – 3) 1.5 (0 – 5) 
cSS presence 4/1372 (0.3%) 1/14 (7.1%) 
0 455/1372 (33.2%) 6/14 (42.9%) 
1 607/1372 (44.2%) 6/14 (42.9%) 
GCA score 
2 - 3 310/1372 (22.6%) 2/14 (14.3%) 
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Table 3: Associations between variables and sICH 
Hazard ratios (with 95% CI) in univariable analysis are shown for each study variable. 
Multivariable hazard ratios refer to a model incorporating all variables with p < 0.2 in 
univariable analysis. 
Characteristic Univariable HR P value Multivariable HR P value 
Age 1.04 (0.98 – 1.09) 0.22 NA NA 
Female sex 0.82 (0.27 – 2.43) 0.72 NA NA 
Hypertension 0.79 (0.28 – 2.29) 0.67 NA NA 
Diabetes 3.88 (1.35 – 11.2) 0.012 3.91 (1.34 – 11.4) 0.012 
>10 BGPVS 10.8 (3.01 – 38.7) 0.000 8.96 (2.41 – 33.4) 0.001 
>10 CSOPVS 1.06 (0.37 – 3.01) 0.92 NA NA 
Lacune presence 2.97 (1.03 – 8.57) 0.044 1.54 (0.52 – 4.59) 0.43 
CMB presence 3.80 (1.33 – 10.8) 0.013 2.61 (0.90 – 7.54) 0.077 
ARWMC score 1.07 (0.86 – 1.34) 0.55 NA NA 
GCA score: 1 0.76 (0.25 – 2.37) 0.64 NA NA 
                    2 - 3 0.52 (0.11 – 2.59) 0.43 NA NA 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
WERRING 25 
Table 4: sensitivity analyses 
Multivariable hazard ratio (with 95% CI) is shown for each variable in each model tested. 
 
Model Components Multivariable HR 
1 >10 BGPVS 11.5 (3.20 – 41.3) 
 Diabetes 4.37 (1.51 – 12.6) 
2 >10 BGPVS 9.46 (2.6 – 34.2) 
 CMB presence 2.84 (0.99 – 8.17) 
3 >10 BGPVS 9.55 (2.60 – 35.1) 
 Lacune presence 1.77 (0.60 – 5.20) 
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Figure 1: Study flowchart 
 
 
Figure 2: Cumulative probability of symptomatic ICH by BGPVS rating 
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